FOLD
Price
$7.65
Change
+$0.01 (+0.13%)
Updated
Aug 28 closing price
Capitalization
2.36B
68 days until earnings call
VRTX
Price
$392.17
Change
+$0.12 (+0.03%)
Updated
Aug 29, 01:21 PM (EDT)
Capitalization
100.52B
61 days until earnings call
Interact to see
Advertisement

FOLD vs VRTX

Header iconFOLD vs VRTX Comparison
Open Charts FOLD vs VRTXBanner chart's image
Amicus Therapeutics
Price$7.65
Change+$0.01 (+0.13%)
Volume$3.62M
Capitalization2.36B
Vertex Pharmaceuticals
Price$392.17
Change+$0.12 (+0.03%)
Volume$1.19K
Capitalization100.52B
FOLD vs VRTX Comparison Chart in %
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. VRTX commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Buy and VRTX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (FOLD: $7.65 vs. VRTX: $392.05)
Brand notoriety: FOLD and VRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 92% vs. VRTX: 88%
Market capitalization -- FOLD: $2.36B vs. VRTX: $100.52B
FOLD [@Biotechnology] is valued at $2.36B. VRTX’s [@Biotechnology] market capitalization is $100.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileVRTX’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • VRTX’s FA Score: 0 green, 5 red.
According to our system of comparison, FOLD is a better buy in the long-term than VRTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 5 TA indicator(s) are bullish while VRTX’s TA Score has 6 bullish TA indicator(s).

  • FOLD’s TA Score: 5 bullish, 4 bearish.
  • VRTX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than FOLD.

Price Growth

FOLD (@Biotechnology) experienced а +0.66% price change this week, while VRTX (@Biotechnology) price change was -1.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.14%. For the same industry, the average monthly price growth was +15.09%, and the average quarterly price growth was +29.14%.

Reported Earning Dates

FOLD is expected to report earnings on Nov 05, 2025.

VRTX is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (-1.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($101B) has a higher market cap than FOLD($2.36B). VRTX YTD gains are higher at: -2.645 vs. FOLD (-18.790). VRTX has higher annual earnings (EBITDA): 4.59B vs. FOLD (33.1M). VRTX has more cash in the bank: 6.38B vs. FOLD (231M). FOLD has less debt than VRTX: FOLD (443M) vs VRTX (1.53B). VRTX has higher revenues than FOLD: VRTX (11.4B) vs FOLD (571M).
FOLDVRTXFOLD / VRTX
Capitalization2.36B101B2%
EBITDA33.1M4.59B1%
Gain YTD-18.790-2.645710%
P/E RatioN/A27.88-
Revenue571M11.4B5%
Total Cash231M6.38B4%
Total Debt443M1.53B29%
FUNDAMENTALS RATINGS
FOLD vs VRTX: Fundamental Ratings
FOLD
VRTX
OUTLOOK RATING
1..100
2212
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
10055
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4865
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
2975

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (63) in the Biotechnology industry is in the same range as VRTX (72). This means that FOLD’s stock grew similarly to VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (55) in the Biotechnology industry is somewhat better than the same rating for FOLD (100). This means that VRTX’s stock grew somewhat faster than FOLD’s over the last 12 months.

VRTX's SMR Rating (100) in the Biotechnology industry is in the same range as FOLD (100). This means that VRTX’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's Price Growth Rating (48) in the Biotechnology industry is in the same range as VRTX (65). This means that FOLD’s stock grew similarly to VRTX’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as VRTX (100). This means that FOLD’s stock grew similarly to VRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDVRTX
RSI
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
66%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
56%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
43%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
39%
Advances
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
59%
Declines
ODDS (%)
Bearish Trend 19 days ago
77%
Bearish Trend 4 days ago
41%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
53%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
35%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IJK95.960.57
+0.60%
iShares S&P Mid-Cap 400 Growth ETF
GEMD41.690.23
+0.54%
Goldman Sachs Access Emrg Mkts USD BdETF
SHDG30.99N/A
N/A
Soundwatch Hedged Equity ETF
LDRC25.32N/A
-0.01%
iShares iBonds 1-5 Year Corporate Ladder ETF
GSSC74.59-0.03
-0.04%
Goldman Sachs ActiveBeta® US SmCp Eq ETF

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+0.13%
VCYT - FOLD
43%
Loosely correlated
+4.68%
ATXS - FOLD
42%
Loosely correlated
+0.31%
IRON - FOLD
41%
Loosely correlated
-0.48%
ROIV - FOLD
40%
Loosely correlated
-0.42%
XENE - FOLD
40%
Loosely correlated
-0.69%
More